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Introduction 
 
As the revolution in the life sciences progresses it is becoming ever more difficult to 
differentiate between chemistry and biology.  When thinking about weapons agents, 
therefore, it is important to consider a biochemical threat spectrum rather than separate 
chemical and biological threats.  A biochemical threat spectrum ranges from classical 
lethal chemical weapons agents through dangerous industrial chemicals to mid-spectrum 
agents such as toxins and bioregulators and on to traditional and genetically-modifed 
biological agents.1 
 
Bioregulators are chemical signalling molecules within the organism such as 
neurotransmitters in the nervous system, hormones in the endocrine system, and 
cytokines in the immune system.2 Such chemicals are appropriately covered by the 
Chemical Weapons Convention (CWC), but they may also be considered to be included - 
by the term “toxins” in Article I - in the prohibition in the Biological and Toxin Weapons 
Convention (BTWC).  Certainly, concerns about bioregulators have been raised in the 
background papers on scientific and technological developments prepared for successive 
review conferences of the BTWC.3 
 
It is well known that a number of states have pursued programs intended to develop 
agents with specific effects on the nervous system of a quite different order from 
traditional (irritant) riot control agents.  For example, the United States weaponized BZ in 
the 1960s4 and Iraq was reported to have a psychoactive agent, Agent 15, in the 1990s.5 
Furthermore, an agent (or agents) of this type were used to break the Moscow theatre 
hostage crisis in late 2001.6 The intention here, however, is to concentrate on the program 
carried out in the United Kingdom during the 1960s, since much of the relevant official 
documentation has recently become available. 
 
Some of this material has already been subjected to extensive research, for example in the 
detailed chronology, Disabling Chemical Weapons, produced by Perry Robinson,7 and in 
the book Gassed by Evans,8 where one chapter deals with the experimentation on human 
subjects with such materials.  What I wish to do here is to concentrate on the questions of 
what the scientists were trying to do and what they achieved. 
 
Before proceeding, however, it is necessary to be clear that, as Carter and Pearson 
explained in their history of British chemical weapons capabilities, the UK at this time 
did have an offensive program.9 The relevant minutes of the Cabinet Defence Committee 
meeting of May 1963, chaired by Prime Minister Harold Macmillan, agreed to a proposal 
from the Minister of Defence which included:10 
 
“an increase in research and development on lethal and incapacitating chemical 
agents and the means of their dissemination (£0.64 million over five years),[and] 
limited production of a chemical agent (£1.5 million over five years)” 
 
However, it was also agreed that “the agents produced as a result [of the program] should 
not be deployed at present.”  It appears that the program came to a halt within about a 
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decade and that no significantly usable incapacitants were discovered.  This gives us a 
quite constrained period of activity, therefore, to examine. 
 
The Program 
 
The United States had begun investigating potential incapacitating agents in the early 
1950s and their program was much larger than that carried out in the UK.  The chapter on 
“Incapacitants” in the US Textbook of Military Medicine of 1995 states:11 
 
“Virtually all drugs whose most prominent effects are psychological or behavioral 
(sometimes referred to as  psychochemicals) can be classified into four fairly 
discrete categories: stimulants, depressants, psychedelics, and deliriants” 
 
Examples of these different types of drugs are shown in Table 1. 
 
 
Table 1: Psychochemical Agents* 
 
Stimulants 
 
Amphetamines (phenylethylamines), cocaine, caffeine, nicotine. 
 
Depressants 
 
Barbiturates, morphine, morphine analogs, antipsychotic (neuroleptic) major tranquilizers 
such as haloperidol and other butophenones. 
 
Psychedelics 
 
D-lysergic acid diethylamide (LSD) and analogs, psilocybin, ibogaine, harmine, synthetic 
psychedelic drugs such as MDMA (ecstasy), phencyclidine. 
 
Deliriants 
 
Atropine, scopolamine and other anti-cholinergics such as BZ, many other drugs in large 
overdoses. 
 
From reference11
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Available Data 
 
The center of the British work, of course, was Porton Down in Wiltshire, then called the 
Chemical Defence Experimental Establishment (CDEE).  A series of major Porton 
Technical Papers from that period have become available at the Public Record Office in 
London.12 One point that is immediately obvious is that intensive work on incapacitants 
preceded the Cabinet decision of May 1963.  This is hardly surprising since the UK had 
been informed of the ongoing US program through the Tripartite Conferences on 
Toxicological Warfare and at the Thirteenth Conference in September 195813 it had been 
agreed that all three countries [the US, the UK, and Canada] should concentrate on the 
search for incapacitating and new type lethal agents.”   At the Fifteenth Meeting,14 held at 
Porton in September 1960, a recommendation was also made that there should be ”the 
granting of highest priority in agent-munition programmes to research and development 
of incapacitating agent systems, together with development of user concepts.”  Clearly 
then, to properly understand the British program, it is necessary to consider work carried 
out prior to the Cabinet decision. 
 
It is possible to gain an overview of the evolution of the program from a series of bi-
annual and annual reports and commentaries on all work at Porton - and reports to the 
Tripartite Conferences - that are available in the Public Record Office.  Additionally, the 
listing of collected papers from the Chemical Defence Experimental Establishment for 
196215 and 196416 detail three publications17,18,19 in the open literature which are clearly 
related to the ongoing studies of incapacitants at Porton.  Furthermore, as early as 1964, 
there were press reports of work on LSD at Porton,20 and of studies of the effects of LSD 
on troops by 1969.21 
 
This rather open view of the work carried out in the program could possibly be connected 
with a comment made by an official on the Chemical Defence Advisory Board-Annual 
Review for 1964 to the effect that:22 
 
“we understand US and UK scientific opinion is that it is not feasible to produce 
an incapacitating agent which will not cause some harmful or even lethal direct 
effects.” 
 
Whatever the reason, a series of papers by the same Porton authors as for the Technical 
Papers were published in the open literature during the 1960s and 1970s.  There was also 
a collection of papers from a symposium held at Porton and co-edited by R. W. 
Brimblecombe in 1972,23 and several books by the same author in the early 1970s.24,25,26 
 
The work at Porton, and any associated extra-mural research elsewhere was reported to a 
series of secret committees.  These committees, in addition to civil servants and military 
personnel, had numerous eminent British civil scientific specialists serving who are 
readily recognisable in the relevant copies of the yearly Who’s Who.  For the period of 
interest here, particularly from April 1960, the Advisory Council on Scientific Research 
and Technical Development had overall responsibility:27 
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“To consider and initiate new proposals for research and development and to 
review research and development in progress in War Office establishments and 
extra-murally, in relation to the most recent advances in scientific knowledge.” 
 
A number of Boards reported to the Council, and of particular interest here is the 
Chemical Defence Advisory Board which had:28 
 
“To review and advise on problems concerning chemical warfare research and 
development carried out in the War Office and extramurally.” 
 
In its turn, this board had several committees: the Biology Committee, the Chemical 
Committee, the Defensive Equipment Committee, the Offensive Evaluation Committee 
and the Physics and Physical Chemistry Committee.  In 1961 it also had an Enzyme 
panel.  In late 1964 it was decided that from 1 April, 1965:29 
 
“(1)  The Enzyme Panel be disbanded; 
(2)  a new Biology Committee be appointed to be concerned with the basic 
medical sciences; 
(3)  an Applied Biology Committee be set up to be concerned with the applied 
sciences (medicine, psychology, etc.)” 
 
The minutes of many of the meetings of the Council, Board and Committees have been 
made public.  Additionally, many reports presented to these bodies on the progress of the 
research on incapacitants have also been released.  However, as the subject of human 
testing has been amply reviewed by Evans,30 I have not concentrated on that issue here. 
 
Previous Research 
 
The chapter of the US text on military medicine dealing with incapacitants concluded in 
the mid-1990s that only one group of chemicals - within the category of those producing          
delirium - were likely to be used as military incapacitating agents. This group of 
chemicals are known as anticholinergics because they block the effect of the 
neurotransmitter chemical acetylcholine at one type of synapse -muscarinic-(that is, at 
synapses where the normal effect of acetylcholine is mimicked by muscarine,an extract 
from a mushroom).31  One particular chemical from this group - known as BZ (3-
quinuclidinyl benzilate) - was weaponised by the United States during the 1960s32 and its 
mode of action is widely understood.33 
 
There have been two previous studies of aspects of the British search for an effective 
incapacitant during the 1960s.  In 1997 Caitriona McLeish analysed the problem of 
governance of dual-use technologies and within that subject considered the work of 
CDEE on TL2636, a derivative of thebaine.34 In 2001 Kathryn McLaughlin considered 
the British work on LSD (lysergic acid diethylamide) in a detailed case study.35  McLeish 
records how British post-war work initially concentrated on the newly discovered lethal 
nerve agents and then on how the new riot control agent CS (a physical irritant) became 
important “in aiding a more orderly retreat from the Empire.”  Together with growing US 
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enthusiasm and the successful use of new drugs in psychiatry, she argues, this raised 
interest in finding yet more powerful mental incapacitants (psychochemicals) that altered 
the target’s state of mind and thus physical performance.  As in the United States, the 
British military search for such incapacitants was assisted by information from industry 
and Mcleish explains how TL2636 was provided by an industrial company.  The 
substance, which has pharmacological effects similar to those of morphine, was tested an 
animals and then on humans, but she suggests that cuts in British defence expenditure in 
the mid-1960s precluded any move to weaponisation. 
 
Kathryn McLaughlin gives a detailed account of the development of British policy in the 
1950s and 1960s and then focuses her attention particularly on the work on LSD.  She 
describes how LSD acts at certain types of serotonin (5-hydroxytryptamine) 
neurotransmitter synapses and ”sets off a complex cascade of events within the central 
nervous system.”  It was of considerable interest because it was effective at low dosages 
and had a very high ratio between effective incapacitating and lethal doses.  McLaughlin 
explains that whilst LSD met many of the criteria required for an effective incapacitant, it 
was then very expensive to manufacture and extremely variable in the behavioural effects 
it produced.  British research included laboratory tests on animals and humans and three 
major field trials involving volunteers. 
 
The tests and trials are described in some detail by McLaughlin.  She notes that LSD was 
rejected not only because of the expense of production and the unpredictability of its 
effects but also because it was difficult to aerosolise and the effective dose by inhalation 
was quite high.  What is obvious from both of these accounts is that a determined effort 
was made in the UK to find an effective incapacitant. 
 
The next section uses the publicly available documentation to attempt a year-by-year 
account of the development of the whole program. 
 
Annual Accounts 
 
Before 1963 
 
Whilst work at Porton in the mid-1950s was still much concerned with defence against 
the nerve agents36 and development of the CS riot control agent,37 studies of the 
physiological effects and mechanism of action of LSD had commenced by 1956.38  
Systematic work on new agents as a whole was underway in 1957 when a working party 
was set up at CDEE.  This working party had already held twelve meetings by the time its 
survey of the literature for leads to the development of new agents was discussed by the 
Chemistry Committee in March 1959.39  The survey itself had eleven sections: review of 
the deliberations and conclusions of the U.S. Advisory Committee; drugs causing mental 
derangement; screening tests for psychotomimetic drugs; antibiotics; venoms; specific 
enzyme inhibitors; neuromuscular blocking agents; ganglion blocking agents; alkaloids; 
cardioactive steroids; and interim conclusions.  Both lethal and incapacitating new agents 
were being sought, but in regard to incapacitating agents it was suggested that 
investigations should begin on indolealkylamines and atropine-like substances if 
 7
satisfactory testing methods could be developed.  This was agreed by the committee, and 
reported on up to the Advisory Council on Scientific Research and Technical 
Development.40 Yet at the end of 1960 it was noted at the Third Meeting of the 
(reconstituted) Advisory Council on Scientific Research and Technical Development that 
the search for new agents had been going on for some years without any clear lead 
emerging and that:41 ”[T]he present indication was that it would be very difficult to find 
an agent with a worthwhile incapacitating effect which would not result in either death or 
permanent injury.” 
 
In regard to agents that might potentially cause incapacitation by interfering with the 
functions of the central nervous system, a wide range of possibilities were already being 
investigated by 1960.  Dr. Downing reported on the ongoing work on indoles to the 
Chemistry Committee in late 1959.42 He also introduced a paper to the committee in mid-
1960 updating the work on indoles and also mentioning work on analogues of tremorine 
amongst other agents.43  The annual review of the Chemical Defence Advisory Board for 
1961 noted ongoing work on tryptamines and indoles and on agents that might disturb the 
balance of gamma amino-butyric acid in the brain. The report also noted the fact that the 
industrial liaison program visits to industrial firms were proving to be valuable and 
approximately thirty firms had been visited. 
 
One of the major problems faced by the investigators was how to screen the potential 
agents in animal tests and to have some means of moving on from tests on animals to 
operational agents45--that is, to testing on humans beings.  Despite the difficulties, the 
effects of injecting the pyrogen Pyrexol were reported to have been tested on 27 men in 
1959,46 and there was clearly a determination to move on to more human testing.  Human 
testing of psychotomimetic substances was started in late 1961.47 One reason for the 
urgency was an increasing perception of the need for a militarily useful chemical 
incapacitant.  As the     Operational Evaluation Committee noted in early 1960:48 
 
 “To satisfy the operational requirements, apart from CS which is probably 
unsuitable because of the short period of incapacitation, there were no other 
substances which could yet be recommended as military incapacitating agents.” 
 
The scientific difficulties faced by the investigators remained formidable.  
 
The United Kingdom’s approach to these difficulties was set out in a discussion paper for 
the Fifteenth Tripartite Conference in 1960.49 This paper suggested that there were two 
main lines of approach in the search for new agents: the biochemical and the 
pharmacological.  In the biochemical approach, “the possibility of interfering with 
various essential systems within the body is considered.”  The pharmacological approach 
was considered more empirical and “consists in searching for drugs with effects which 
may be incapacitating.”  A third “physiological” approach involved looking at various 
body functions and how they might be disrupted.  Crucially, the paper pointed out: 
 
“Ideally, the best possible method for preparing a new agent with a given action 
would be to design a molecule which would have this specific type of action.” 
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However, it noted that “knowledge of structure-activity relationships is not sufficiently 
exact for this to be possible” (emphasis added).  Thus another approach was an entirely 
empirical one in which a wide-ranging literature survey might ”perhaps by chance” throw 
up promising leads.  Given the importance of knowledge of structure-activity 
relationships for the design of new agents, the obvious attraction of compounds with 
structural or functional relationships to the small number of neurotransmitters then 
known is understandable. 
 
Transmission of information within the individual cells (neurons) of the nervous system 
is by electrical means, but transmission between neurons, or between neurons and 
effector organs (such as muscles) is predominantly by chemical means.  We now know 
that the neurotransmitter chemical has to be specific for the receptor sub-type at the 
junction (synapse) and that a variety of mechanisms ensure that the transmitter acts only 
for the precise period required.50  The investigators were obviously interested in 
muscarinic acetylcholine synapses because they knew how nerve agents prevented 
destruction of the transmitter by binding to the enzyme that normally destroyed it and that 
atropine could be used to block the neuronal receptors and thus help to avoid the 
consequences of excess acetylcholine.  They also knew something about the operation of 
monoamine neurotranmitters such as epinephrine, norepinephrine and dopamine 
(catecholamines), and serotonin (5-hydroxytryptamine) which is an indoleamine.  The 
initial decision to concentrate work on atropine-like substances and indoleamines is 
therefore understandable, as is the interest in gamma aminobutyric acid which was also 
known as a neurotransmitter. 
 
Against that background it is not surprising that studies were made of the inhibition of 
monoamine oxidase and presented in a detailed series of Porton Technical Papers during 
the late 1950s and 1960.51  This enzyme was thought to “play an important role in the 
metabolism in the brain of endogenous catecholamines and indolealkylamines such as 
noradrenaline [norepinephrine] and 5-hydroxytryptamine” so it was hoped to find ways 
of severely interrupting its function and thus causing incapacitating effects. 
 
The research program underway at Porton in the early 1960s can be clearly visualised 
from the series of Porton Technical Papers for 1961 and 1962.  Three papers addressed 
the problem of biological testing of incapacitants in animals.  The first of these reviewed 
available testing methods,52 the second assessed the results, in such tests, of using drugs 
with known effects on humans53 and the third       considered the screening of new 
compounds using the available tests.54  The tests used were of four types: firstly, general 
tests such as the effect on body temperature; then tests for physical incapacitation such as 
reduced ability to climb an inclined rod; thirdly there were a series of simple behavioural 
tests such as the effect of a drug on the way on animal behaved when put into a relatively 
open space (Hall’s Open Field Test); and finally, more complex measures of the effects 
of a drug on the results of a learned avoidance test.  Such more complex tests were the 
subject of a further paper in mid-1962.55 
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At the same time a variety of potential agents such as simple peptides,56 indoles and 
tryptamines,57 and N-N-dialkyltryptamines58 were being synthesised and subjected to 
screening.59  Sometimes, also, as discussed by McLeish,60 the industrial liaison program 
produced a chemical thought worthy of further intensive study.61  A detailed report on the 
then current position in the search for new agents, and future intentions for the research, 
was given at the Chemistry Committee’s 42nd meeting in 1962.62  In regard to 
”Incapacitating Compounds,” this reported work on indoles and tryptamines, tremorine 
and derivatives, substituted hydroxylamines and hydrazines (to interfere with gamma 
aminobutyric acid metabolism), pyrroles, benzimidazoles (which have an analogous 
structure to indoles) and a variety of irritants and miscellaneous products. 
 
Dr. Downing also gave a review of the work on incapacitating agents to the ninth meeting 
of the Offensive Evaluation Committee in January 1962.63  He stated that there were 
three lines of investigation: systematic literature review; liaison with industrial 
laboratories and universities; and research stimulated at CDEE (Porton).  The policy had 
been to explore the maximum number of possibilities and to keep the laboratory work to 
the minimum needed to determine whether a substance was of interest.  Dr. Downing also 
noted that two major leads were being followed up in the United States.  These were 
quinuclidinyl benzilate (EA2277/BZ) and tetrahydrocanabinol (EA1476/marihuana).  He 
explained that whilst the US was concentrating on mental incapacitation, the UK was also 
interested in physical effects such as that produced by the oripavine derivative T.L.2636 
(which in low doses caused nausea and vomiting and sensations similar to motion 
sickness).64 
 
However, as the director of Porton, Mr. Haddon, explained to the Chemical Defence 
Advisory Board in May 1962,65 for the past five or six years the work at CDEE had been 
guided by a policy directive ”to study and develop means . . . to defend ourselves against 
chemical warfare” (that is, a defensive program).  Now he reported on ”the various signs 
that this somewhat restrictive policy directive would be changed” and that “CW with 
incapacitating agents would probably not be open to the same political objections [as 
lethal CW] and increasing research and development effort up to full weapon 
development was therefore favoured.”  In the new circumstances he anticipated CDEE 
would receive increased funding and increased staffing but in the meantime “they were 
re-arranging their research program to give increased emphasis to incapacitating agents 
and means for their dispersal.” 
 
1963 
 
At the 53rd meeting of the Chemical Defence Advisory Board on 6th June 1963 Mr. 
Haddon noted,66 in a discussion of “[N]ew agents research”, that “CDEE now had a 
directive for the development of incapacitating agents, so they had been right to study 
these compounds.”  At the next meeting of the board a top secret paper on the UK’s 
chemical warfare policy was tabled, but not circulated.  It was stated that the services had 
formulated their new requirements for phase I (1964-1969) and some proposals had been 
put forward in regard to phase II (1969-1974).67  Yet there were clearly problems, for 
example in obtaining suitable staff68 to carry out the work and in obtaining sufficient 
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human volunteers for tests.  Part of the program was clearly carried out not only through 
industrial liaisons, but also through extra-mural research contracts.69 
 
The December 1963 report to the Chemistry Committee, on “[N]ew agent research” 
contained an interesting development in regard to the work on tremoram.70  It stated that 
this compound had effects at muscarinic acetylcholine receptors and discussed the 
structural requirements necessary for it to have an effect at the receptor.  Three Porton 
technical papers investigated these issues in considerable detail.71,72,73  The December 
meeting also considered the preparation and properties of BZ.  This had been the subject 
of a Porton Note which was based on information in US reports.74 Whilst the search for 
new related compounds was being left to the United States, the UK was evaluating BZ 
and one related compound (EA3443) which was considered to be an important new 
finding. 
 
1964 
 
At a meeting of the Advisory Council in Nombember 196475 General Sir John Hackett 
stated that “it was very desirable to find a safe incapacitating agent. . . . General Staff 
Targets had been issued.”  The increased service interest in chemical warfare was also 
clear from the major troop exercise TUREEN76 which was the first ”for many years to 
include situations involving the use of chemical warfare.” 
 
In this situation the new agents search was clearly important.  At the Chemical Defence 
Advisory Board’s meeting in June 196477 there was a report of the 48th meeting of the 
Chemistry Committee.  The report stated that: 
 
“There had been five papers on new agent research relating to psychotomimetic 
compounds and compounds acting on the central nervous system.  These papers 
covered the preparation and testing of a number of variations of known active 
structures and represented a useful addition to knowledge.” 
 
One of these papers dealt with the search for pharmacologically active benzimidazoles.78 
The paper noted that studies of these compounds had been reported in three Porton 
Technical Papers (859, 895, 896).  The compounds, which resemble tryptamines, were 
considered for possible effects on the central nervous system but the effects detected 
”were due to toxic action on the heart” and not on the central nervous system.  Further 
work was therefore not contemplated, particularly as the French had become interested in 
this field of work. 
 
The meeting of the Chemical Defence Advisory Board in October 1964 considered the 
CDEE annual report for the period ending 30th June 1964.  The report on new agents 
stated that some 150 compounds had been screened during the year with some 10-15 per 
cent of these coming from industry or universities.79 Particular note was made of work on 
compounds possessing muscarinic activity and on oripavine derivatives, while work on 
indoles and tryptamines also continued.  At the UK’s production site (Nancekuke) work 
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also continued on the problem of synthesising large enough quantities of compounds for 
testing. 
 
More detailed figures are also available in the fourth of the series of Porton Technical 
Papers on Biological Testing of Incapacitating Agents.80  During the period August 1961-
December 1963 240 new compounds had been received for testing as potential 
incapacitating agents, and of these: 
 
“It is considered that two tryptamine derivatives, one pyrrole [related to indoles], 
one phthalimide, four oripavine derivatives, one hydrazine [which might inhibit 
monoamine oxidase], tremoram and three allied compounds, and three 
compounds of a miscellaneous nature” 
 
warranted further study. 
 
Also in 1964, two papers appeared in the open literature that were written by staff at 
Porton involved in the search for new incapacitating agents.  [Dr. Downing had a major 
review of the literature on psychotomimetic compounds published whilst stationed at the 
British Embassy in Washington81 and also co-authored a paper with Brimblecombe, 
Green and Hunt82 on tryptamine derivatives in which their Porton Down CDEE address 
was given.  As Mr. Haddon had pointed out in 1963,83 staff were encouraged to publish 
in the open literature and “even if the application of work was classified, security 
difficulties could be overcome by employing suitable means of presentation.” 
 
1965 
 
Difficulties with staff recruitment and retention, particularly in the medical division at 
CDEE, continued in 1965.  A report to the Advisory Council84 in April noted that “they 
had been unable recently to find medical staff to control the tests of incapacitating agents; 
as a result that work had had to be stopped.”  Yet the Council, in its annual report85 for 
1965, stressed the perceived importance of the work, “[W]e consider that experiments on 
this humane type of warfare should be pressed forward with all speed.” 
 
In introducing the CDEE report for 1964-1965 to the Chemical Defence Advisory Board, 
Mr. Haddon said that it dealt essentially with the first year of the expanded program:86 
 
“The original concept had been five years of steady expansion, the first two of 
which would be devoted to the recruitment of staff, the third to the acquisition of 
laboratory apparatus and equipment and the fourth and fifth to the development of 
more sophisticated equipment and techniques.” 
 
Interestingly, when the board visited CDEE in May 1965 one of the demonstrations 
provided was of the new neuropharmacology laboratory by R. W. Brimblecombe.87 
 
The 50th meeting of the Chemistry Committee88 was focused on the new agents program.  
Mr.Bebbington presented a review of the program89 and made it clear in his presentation 
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that the New Agents Committee at CDEE was still in operation and making 
recommendations for further work.  R. R. Hunt presented a review of CDEE work on 
indole derivatives from 1959-1964.90 This paper noted that Downing, in 1959, concluded 
that at that time “the derivatives of indole were most likely to provide new compounds 
with high activity.”  The research on indoles had resulted in seven Porton Technical 
Papers (739, 892, 771 and 822, 770, 915 and one in preparation).  However, because of 
“the limited incapacitating effect, at relatively high doses,of the simple tryptamines, and 
the higher lethality of the more active ring-substituted tryptamines” it was recommended 
that no further synthetic work should be carried out on simple indoles and tryptamines. 
 
A further paper by R. W. Brimblecombe and D. G. Rowsell considered the interaction of 
muscarinic drugs with the post-ganglionic cholinergic receptor and supported the idea of 
a three point interaction between drugs and the receptor.91  This paper was obviously 
related to a series of Porton Technical Papers (912, 913, 914) dealing with aspects of this 
topic, and a major paper by Bebbington and Brimblecombe92 covering the same topic 
appeared in the open literature during the year. 
 
The state of the program of chemical and medical research on new agents can be gained 
from a prepared summary of the CDEE annual report for 1964-1965.93 This stated that 
about 150 compounds, mainly potential incapacitants, had been examined during the 
year.  There had been a steady decline in the number of human volunteers for testing 
from 306 in 1962-1963 to 167 in the year of the report, but this had been offset to an 
extent by people volunteering for longer.  The main lines of the intra- and extramural 
research described in the report are shown in Tables 2A and 2B.  Work had also 
continued on finding better methods of assessing incapacitating effects, and the report 
noted that as many potential incapacitants were solids at normal temperatures research on 
dispersal mechanisms was being carried out as well. 
 
As is evident from Table 2A, work with LSD25 included a small-scale field trial of its 
effects on trained troops.94  The film of the exercise was shown at the first meeting of the 
new Applied Biology Committee in November 196595 and Mr. Haddon explained that the 
main questions of interest to CDEE were: 
 
“(a) whether it was effective when administered by inhalation, and the effective 
dose . . . (b) whether it was a substance procurable in reasonable supply (c) its 
effects on a troop of men in a military context, and (d) means of defence aginst its 
use.” 
 
Clearly, such field trials of incapacitants were a major departure for the program. 
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Table 2A: Lines of Intramural Research* 
 
1. Oripavine (TL.2636) 
 
Efforts are being made to synthesise simpler, but closely related compounds having the 
same type of activity...Biochemical studies are in progress to determine the mode of 
action of compounds of this type. 
 
2. Tremoram Series 
 
Work...has been directed towards elucidating their mode of action and determining the 
type of chemical structure required for maximum activity. 
 
3. Mental Incapacitant LSD25 
 
Experiments...have included a small scale field exercise (Moneybags). 
 
4. Other potential incapacitating agents 
 
Work...continuing includes that on the indoles, indoline and pyrimidine series of 
compounds.  Naturally-occuring materials are also explored as possible sources of highly 
active compounds. 
 
* From reference93
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Table 2B: Lines of Extramural Research* 
 
Professor Olli (Sheffield University) 
 
Natural Products 
 
Professor Rydon (Exeter University) 
 
Ricin 
 
Professor Thompson (Guy’s Hospital Medical School) 
 
Snake venoms 
 
Professor Tatlow (Birmingham University) 
 
Hydrocarbons containing fluorine 
 
Dr. Mary Pickford (Edinburgh University) 
 
Synthetic peptides 
 
Professor Williams (St. Mary’s Hospital Medical School) 
 
Liver metabolism of drugs (effects of various substances) 
 
Professor Wilson (Liverpool University) 
 
Ultramicro methods of carrying out biochemical studies on drugs 
 
* From reference93
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1966 
 
The Chemical Defence Advisory Board visited CDEE in June 1966.  Mr. Haddon, the 
CDEE Director, told them that CDEE reported to the Master-General of the Ordnance 
and, on scientific issues, to the Chief Scientist (Army).96  The total staff of CDEE was 
about 900 people.  There were 71 approved Scientific Officer, three Medical Officer 
(Research), 120 Experimental Officer and eight Engineer posts.  The United States 
appointed a full-time Liaison Officer to work at Porton.  The main areas of investigation 
in CDEE’s research program were set out in the 1966 Annual Review.97  These included, 
within Operational Assessment, studying ”the operational effectiveness of incapacitating 
agents.”  According to the chair of the Board, new agent research occupied about one 
fifth of the Establishment’s research effort.98 
 
In his presentation to the Board, during their June 1966 visit, Dr. Bebbington summarised 
how work had been narrowed down:99 
 
“four main types of drug effect should be examined in detail at this stage.  The 
fields chosen were those drugs affecting cholinergic systems, including the 
psychotomimetic anticholinergics; those affecting adrenergic systems; those, 
mainly morphine-like, causing depression of the central nervous system; and 
those, other than anticholinergics, having psychotomimetic properties” (emphasis 
added). 
 
Of course, as has been described in detail by Evans,100 there was a considerable emphasis 
at this time on studies of the effects of LSD,101 including another field experiment called 
Recount.102 
 
A 6th Progress Report on Chemical Research on Toxic Compounds by R. R. Hunt103 was 
presented to the 53rd meeting of the Chemistry Committee at Porton on 30 June 1966.104 
The work covered by the report was for the period from the previous report in March 
1963.  The 1966 report began by stating clearly that “[T]he current approach to the 
research on biologically active compounds is based as far as possible on studies of the 
mode of action of drugs at the molecular level.”  Two reports in the open literature105,106 
covered the work on oxotremorine and the investigation of the structure of the muscarinic 
receptor.  Confirming Bebbington’s earlier presentation to the board, the report stated that 
four main types of activity had been chosen for study: cholinergic and anticholinergic 
activity; catecholamine [adrenergic] depletion; CNS depression; and psychotomimetic 
activity.  Respiratory irritation was also covered in the report but is not relevant here.  
What is perhaps of most interest is the appearance of glycollates under the category of 
cholinergic and anticholinergic compounds on which work was being carried out. 
 
The drive towards molecular studies was emphasised in comments made on the CDEE 
Annual Report by Professor R. B. Fisher, chair of the Chemical Defence Advisory 
Board.107 Fisher noted that new agent research accounted for 15 per cent of CDEE’s total 
activity and 20 per cent of all its research activity.  However, it seemed to him that with 
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some regularity the first lead in a new class of compound was found to be the most 
effective when many modifications were synthesised.  He asked: 
 
“1. Is it possible that, if more time were devoted to determination of the site of 
action, subsequent synthetic work could be more profitably directed?” 
and: 
”2. Is it possible that a review of the modes of action of very highly toxic 
substances could give help in the search for further such substances?” 
 
In effect, the chair of the board appeared to be asking if the research program was 
misguided in being too directed towards manipulation of the chemistry of potential agents 
rather than towards understanding of the receptor that was the target of the agent. 
 
Moves towards a more systematic approach can clearly be seen in the 1966 Porton 
Technical Papers, for example in an attempt to develop a model that would predict 
biological activity.108 More significantly, amongst a series of Porton Technical Papers on 
the pharmacology of various groups of chemicals (939, 942, 955), one concerning the 
“Pharmacology of Some Anticholinergic Drugs,” Porton Technical Paper 959,109 was 
stated to be the first in a series dealing with this subject. 
 
1967 
 
The studies on incapacitants carried out by CDEE were not done in isolation from the 
armed services.  Mr. Gadsby, Director, Biological and Chemical Defence, told the 42nd 
meeting of the Advisory Council on Scientific and Technological Development110 that 
“the Services attached great importance to requirements identified with the feasibility of 
incapacitating agents,” and at the 65th meeting of the Chemical Defence Advisory 
Board111 Wing Commander Hampton commented that ”the R. A. F. were concerned 
about the possibility that drugs of this type   could be used  to ‘knock out’ an airfield 
without destroying the facilities.”  At the 66th meeting of the board Colonel Nicholson112 
noted the offensive requirement that the Combat Development Directorate had advised, 
that “the ultimate requirement should be for a range of incapacitating agents giving a 
variety of onset times and durations of effect.” 
 
What this might mean, in part, may be gathered from a presentation on 
“Anticholinergics” given by R. W. Brimblecombe113 to the 2nd Joint Meeting of the 
Biology Committee and the Chemistry Committee.  He stated that ”[E]ffects referred to 
as long duration would persist for 3 to 5 days, those of intermediate duration about one 
day, and short acting effects for 2 to 5 hours.”  Given the perceived importance of 
chemical warfare and defence, it is not surprising that Mr. Gadsby reported that the 
ongoing review of defence expenditure would only result in a a small cut being imposed 
on CDEE,114 and later,115 that there would be a reduction of 12 to 13 White Paper 
(research) Grades by 1971 and that ”at this juncture it was not anticipated that this would 
generate any dramatic problems.” 
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The 4th meeting of the Applied Biology Committee116 considered a series of papers on 
the ongoing incapacitants program which give an impression of the changing nature of 
the program in mid-1967.  The papers were: a progress report on work with T.3456 
[LSD]; a report of US experience with BZ and other benzilates and glycollates; a report 
of early exploratory work with BZ in the UK; and a report on future plans for work in the 
UK [on glycollates].  In regard to the American experience with BZ, Moyland-Jones117 
stated: 
 
“The glycollates are glycollic acid esters, benzilates being glycollates containing 
two phenyl rings, while most of the other glycollates of interest contain one 
phenyl and one other group.” 
 
He went on to explain that the pharmacological action of these compounds is 
anticholinergic, and that incapacitation results: 
 
“(a) from the peripheral manifestations notably some ataxia and muscle 
’tiredness’, mydriasis and failure of accommodation and (b) from central effects 
which present a toxic confusional psychosis.” 
 
The severity and duration of the effects depended on the type of glycollate, the dose and 
the route of administration.  All were effective by inhalation, and those which were liquid 
were active percutaneously. 
 
Moyland-Jones went on to state that US work was directed to “finding a compound more 
active than BZ, but with a shorter time of onset of effects and shorter duration of 
activity.”  He gave a table of compounds with ascending order of duration of effects and 
argued that EA3580 was most likely to warrant further investigation and it was also 
active percutaneously. 
 
Kemp’s paper118 on “Future Plans for Work in the UK” added that the US was giving 
priority to four glycollates, “T.3437, with an onset time of about two hours, T.3126, 
T.2532 (BZ) and EA3167 which has a long onset time and may produce effects lasting up 
to three weeks.”  The UK did not intend to duplicate US work but in view of 
discrepancies between US and UK studies it would carry out further work on BZ.  
Additionally, the New Agent Committee had selected two other glycollates for early 
study: 
 
“(i) T.3437, chosen for its quick onset of activity and its short duration of effect. 
(ii) T.3436 a compound with intermediate onset time and intermediate duration of 
effects (as suggested by experiments with animals).” 
 
Porton Technical Paper 959119 had concluded, from detailed study of 19 compounds, that 
“T3436 . . . a compound with high activity, a low ratio between peripheral and central 
activity and an action which is rapid in onset but short in duration might satisfy many of 
the requirements for a mental incapacitating agent“(emphasis added).  The Committee 
also        considered a long paper by Brimblecombe, Beswick and Downing, which 
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attempted a very wide-ranging survey of possible sources for new ideas on incapacitants 
such as data on toxic hazards in industry and on old discarded CW agents which had 
previously only been of interest for their possible lethal effects.120 
 
Amongst other reports received by the committees one on “The anticholinergic properties 
of enantiomeric glycollates” by Brimblecombe and Inch,121 and the associated Porton 
Technical Paper122 were of interest in exploring more deeply how drugs and receptors 
interacted.  Other more detailed work on receptor/drug interactions was reported in 
regard to morphine-like receptors123 and in both the then closed124 and open125 literature 
in regard to cholinergic receptors and interactions.  An interesting illustration of the 
increasing sophistication of the work was the development of a radio-transmitter (Figure 
1) system to monitor cat brain signals during free-ranging behaviour.126
 
1968 
 
The CDEE Annual Report for 1967-1968 reviewed the ongoing work on synthesis and 
biological investigation of potential agents and also reported the purchase of more 
advanced automated apparatus for carrying out the animal testing.127  However, Dr. 
Wilson (Chief Scientist, Army) reported to the Advisory Council in October128 that “the 
situation might be reaching the point at which it would have to be accepted that the 
volunteer system had broken down.”  In that event a service detachment might have to be 
posted to Porton for testing for one or two months as was done in the United States.  
Concerns were also expressed over the bad publicity Porton had recently received. 
 
Even more seriously, at the 50th meeting of the Council129 Mr. Gadsby said ”it was 
important to note that, in keeping with the defence policy of reducing expenditure, CDEE 
had to achieve a cut of £150,000 in annual expenditure by the financial year 1970-1971.”  
It also had to cut White Paper Grades by one and a half per cent per year for three years.  
This, he said, would affect the program and, for example, “less effort would be devoted 
to the search for new incapacitating agents.”  The structure of the Advisory Committee 
system was also being reviewed and the annual report of the Council noted that it would 
be replaced by a new Scientific Advisory Council.130 However, the report concluded that 
work on enantiomeric glycollates should be “vigorously pursued.”  No further trials were 
required on LSD as it was “unlikely to be used as a C.W. agent.”  Moreover, as Dr. 
Barrass explained to the Chemistry Committee,131 “little attention had so far been paid to 
elucidating the mode of action of hallucinogens such as LSD-25 and mescaline.”  Dr. 
Beswick explained to the Applied Biology Committee132 that T.3456 (LSD) was not a 
practical agent because “[T]here were problems of dissemination, the 100% effective 
dose by inhalation was relatively high, and the material was expensive.”  In a report on 
the 6th meeting of the Applied Biology Committee the Chemical Defence Advisory 
Board133 heard that the third field experiment with LSD (Small Change) had been 
satisfactory, but that ”work on TL.2636 (an oripavine derivative) was of academic 
interest only.” 
 
Despite such setbacks, a Joint Meeting of the Applied Biology Committee and the 
Biology Committee in late 1968134 took the form of an extended seminar on “Behavioural 
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Studies” with papers on the study of the effects of psychoactive drugs on animals and 
human beings, the use of electroencephalographical and neurophysiological techniques, 
the behavioural effects of glycollates and so on.  Indeed, work was clearly pressing ahead 
still with studies of glycollates at this stage.135,136,137,138   
 
Assessment 
  
Nevertheless, in a paper for the Offensive Evaluation Committee, Professor Fisher 
stated:139 
 
“On general grounds I think it unlikely that . . . a pure incapacitator agent will 
emerge.  Any chemical agent, a small dose of which is capable of profound 
disturbance of bodily or mental funtion, is certain to be able to cause death in 
large dose . . . and no attack with a chemical warfare agent is likely to be designed 
with the primary objective of avoiding overhitting.” 
 
Professor Fisher’s point was much later amply demonstrated, for agents of the Cold War 
era, by the consequences of using a fentanyl derivative to break the Moscow theatre 
hostage crisis in 2001.140 Professor Fisher was more scathing in a paper141 circulated to 
all of the committees of the Advisory Board in which he stated that: “The notion of an 
incapacitator is a little more magical than scientific.”   
 
Work on these agents clearly continued at least into the early 1970s in the United 
Kingdom.142,143  Yet on the available evidence it seems clear that the UK’s search for a 
chemical incapacitant in the 1960s was unsuccessful.  Whether a similar search today 
would have the same result is unclear in view of the great advances that have been made 
in our understanding of the nervous system, and particularly the structure of receptors for 
neurotransmitters. 
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*This is an extended version of the first section of the chapter on Midspectrum 
Incapacitant Programs in Deadly Cultures (Ed. Wheelis et al), Harvard University Press, 
2005. 
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